Lunaphore is a life sciences company developing technology to enable spatial biology in every laboratory.
Lunaphore is disrupting tissue diagnostics field by fundamentally changing the time and resource driven nature of diagnostic assays on tumor sections.
Lunaphore was founded in 2014 by Ata Tuna Ciftlik, Diego Gabriel Dupouy, and Déborah Heintze. The company is headquartered in Tolochenaz, Vaud, Switzerland.
Lunaphore provides solutions based on a game-changing chip technology that can extract spatial proteomic and transcriptomic data from tumors and other tissues, transforming any assay into multiplex spatial biology with an intuitive approach.
Lunaphore’s technology enables the identification of biomarker “signatures” with clinical relevance to support the development of diagnostic tools and streamline clinical trials, to ultimately improve patient outcomes.
Lunaphore launched COMET™, an ultra-rapid, high-throughput, high insight platform for multiplex immunofluorescence (IF) and biomarker discovery. COMET™ is currently adopted by the worlds leading research institutions.
Lunaphore is backed by EGS Beteiligungen AG (EGSB), PHC Holdings Corporation, Redalpine, Swiss Entrepreneurs Fund, Eurostars, Venture Kick, OCCIDENT, Zürcher Kantonal Bank, Norgine Ventures, and others. The company raised CHF 40M ($43.5M) in a Series D-1 round on Mar 23, 2023. This brings Lunaphore's total funding to $96.3M to date.